MARIA PIMENTEL: Open Payments
NPI 1710522735 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,502 in 213 payments from 19 companies in 2025. Trend: 2023 $3,827 · 2024 $4,002 · 2025 $4,502
Food & beverage: $4,502
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $581 |
| Neurocrine BioSciences, Inc. | 20 | $542 |
| Teva Pharmaceuticals USA, Inc. | 26 | $417 |
| Otsuka America Pharmaceutical, Inc. | 16 | $404 |
| Alkermes, Inc. | 18 | $375 |
| ABBVIE INC. | 17 | $367 |
| Janssen Pharmaceuticals, Inc | 16 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $305 |
| Bausch Health US, LLC | 13 | $286 |
| Vanda Pharmaceuticals Inc. | 9 | $245 |
Products named: CAPLYTA, INGREZZA, AUSTEDO XR, REXULTI, VRAYLAR, ARISTADA, TRINTELLIX, APLENZIN.
Industry payments across FL — which companies pay providers there.
